Caresyntax, a vendor-neutral platform for precision surgery, has successfully secured $180 million in a Series C extension and growth debt expansion round. This total includes $80 million in equity and up to $100 million in growth debt.

Investors in this round include Symbiotic Capital, MTIP AG, BIONIQ Capital, PFM Health Sciences, Pictet Alternative Advisors, surgical.ai, BlackRock Innovation Capital, Aescuvest, Optum Ventures, Cure Capital, Relyens Group, Vesalius Biocapital, Lauxera Capital, Plug & Play Growth Fund, and ProAssurance Corp.

The platform provided by Caresyntax is designed to be medical-grade and interoperable, capturing and utilizing data to improve surgical precision and patient safety.

Serving over 30,000 surgical professionals in more than 3,000 operating rooms globally, Caresyntax offers automation and actionable insights to hospitals, medical device companies, and insurers.

Caresyntax addresses data fragmentation issues that hinder advancements in precision and data-driven surgery within the $3 trillion global surgical market. By integrating and analyzing data using technology and AI, the platform supports clinical decisions in real-time and over the long term, enhancing patient care, hospital efficiency, and overall outcomes.

With operations in the US and EMEA, Caresyntax is experiencing growing demand from both private and public hospitals. The company's track record of reducing costs and improving patient outcomes distinguishes it in the industry.

Since its 2021 Series C funding, Caresyntax has introduced new AI products, expanded into new markets, and achieved over 75% revenue growth in the first half of 2024.

The new funding will facilitate the scaling of surgical tool adoption, advance AI and edge-to-cloud applications, and support M&A activities, including several planned acquisitions for 2024.

The capital raised will strengthen Caresyntax’s financial position, driving growth, platform adoption, and strategic development.




Source: caresyntax.com

Report Abuse